AppLovin: UBS Raises Price Target to $810
UBS hiked AppLovin's stock target to $810, calling it a "top pick". They expect better Axon 2.0 tech and solid advertiser demand.

Already have an account? Sign in.
UBS hiked AppLovin's stock target to $810, calling it a "top pick". They expect better Axon 2.0 tech and solid advertiser demand.
Blackstone and TPG are in advanced talks to acquire medical device maker Hologic for over $17 billion, potentially becoming one of 2025's largest private equity deals.
Mubadala Capital explores acquisition of Clear Channel Outdoor Holdings as outdoor advertising deals heat up globally. Stock jumps 19% on takeover speculation.
Jefferies and Wedbush maintain Buy ratings on Viridian Therapeutics as Roche's thyroid eye disease drug shows weaker results than Viridian's veligrotug therapy.